Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Gastroesophageal reflux disease (GERD)
* Erosive esophagitis healing and maintenance
* Zollinger-Ellison syndrome
* Peptic ulcer disease (duodenal and gastric)
* H. pylori eradication (in combination with antibiotics)
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily. Duration varies based on indication (e.g., 4-8 weeks for healing, then potentially lower dose for maintenance).
* **Zollinger-Ellison Syndrome:** Start with 40 mg orally or intravenously once daily. May titrate up to 240 mg per day divided into doses.
* **H. pylori Eradication:** 40 mg orally twice daily for 7-14 days in combination with antibiotics.
## Pediatric Dosing
Dosing in pediatric patients varies significantly by age and indication. Consult specific pediatric guidelines or institutional protocols.
* **1 month to < 16 years:**
* GERD/Erosive Esophagitis: Oral suspension or delayed-release tablets: 1.25 mg/kg/day once daily, not to exceed 40 mg/day.
* Intravenous: 0.5 mg/kg/dose once daily, not to exceed 40 mg/day.
## Dose Adjustments
* **Hepatic Impairment:** Reduce daily dose to 20 mg orally once daily.
## Contraindications
* Hypersensitivity to pantoprazole or any component of the formulation.
* Use of rilpivirine-containing products.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
Serious: *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with prolonged use, hypomagnesemia, vitamin B12 deficiency, fundic gland polyps.
## Key Drug Interactions
* **Antiretrovirals:** May decrease absorption of certain HIV medications (e.g., rilpivirine, atazanavir).
* **Methotrexate:** May increase levels of methotrexate.
* **Warfarin:** May increase INR and prothrombin time.
* **Ketoconazole, Itraconazole, Erlotinib:** May decrease absorption.
* **Clopidogrel:** Potential for reduced antiplatelet effect, though clinical significance is debated.
## Monitoring
* Electrolytes (especially magnesium) with prolonged therapy or concurrent diuretic use.
* Bone mineral density screening may be considered for patients at risk of osteoporosis.
* Monitor for signs and symptoms of *C. difficile* infection.
* Assess for vitamin B12 deficiency with long-term use.
## Clinical Pearls
* Pantoprazole is generally considered less likely to inhibit CYP2C19 compared to omeprazole, potentially leading to fewer drug interactions with clopidogrel, but this remains a subject of ongoing research.
* For H. pylori eradication, ensure appropriate antibiotic regimen is used.
* Oral formulations should be swallowed whole and not crushed, chewed, or broken. The delayed-release granules/tablets should not be crushed.
* IV administration requires reconstitution and further dilution.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant institutional guidelines before making clinical decisions.
